Abstract:Mammalian target of rapamycin (mTOR) regulates cell growth, cell differentiation and protein synthesis. Rapamycin, an inhibitor of mTOR, has been widely used as an immunosuppressant and anti-cancer drug. Recently, mTOR inhibitors have also been reported to be a potential anti-epileptic drug, which may be effective when used in young patients with genetic epilepsy. Thus, a suitable dose of rapamycin which can maintain the normal function of mTOR and has fewer side effects ideally should be identified. In the present study, we first detected changes in marker proteins of mTOR signaling pathway during development. Then we determined the dose of rapamycin by treating rats of 2 weeks of age with different doses of rapamycin for 3 days and detected its effect on mTOR pathway. Young rats were then treated with a suitable dose of rapamycin for 4 weeks and the effect of rapamycin on mTOR, development and immunity were investigated. We found that the expression of the marker proteins of mTOR pathway was changed during development in brain hippocampus and neocortex. After 3 days of treanent, 0.03 mg/kg rapamycin had no effect on phospho-S6, whereas 0.1, 0.3, 1.0 and 3.0 mg/kg rapamycin inhibited phospho-S6 in a dose-dependent manner. However, only 1.0 mg/kg and 3.0 mg/kg rapamycin inhibited phospho-S6 after 4 weeks treatment of rapamycin. Parallel to this result, rats treated with 0.1 and 0.3 mg/kg rapamycin had no obvious adverse effects, whereas rats treated with 1.0 and 3.0 mg/kg rapamycin showed significant decreases in body, spleen and thymus weight. Additionally, rats treated with 1.0 and 3.0 mg/kg rapamycin exhibited cognitive impairment and anxiety as evident by maze and open field experiments. Furthermore, the content of IL-1β, IL-2, IFN-γ, TNF-α in serum and cerebral cortex were significantly decreased in 1.0 and 3.0 mg/kg rapamycin-treated rats. The expression of DCX was also significantly decreased in 1.0 and 3.0 mg/kg rapamycin-treated rats. However, rats treated with 1.0 mg/ kg rapamycin exhibited fewer and milder side effects than those treated with 3.0 mg/kg. In summary, all these data suggest that there is not a rapamycin dose that can inhibit mTOR for epilepsy without causing any side effects, but 1 mg /kg may be the optimal dose for young rats for suppressing mTOR with relatively few side effects.

Rapamycin Attenuates the Development of Posttraumatic Epilepsy in a Mouse Model of Traumatic Brain Injury

Alterations of the electrophysiological properties from cortical layer 5 pyramidal neurons in temporary rapamycin-treated rodent brain slices.

Mapping The Spatio-Temporal Pattern Of The Mammalian Target Of Rapamycin (Mtor) Activation In Temporal Lobe Epilepsy

The Post-Therapeutic Effect of Rapamycin in Mild Traumatic Brain-Injured Rats Ensuing in the Upregulation of Autophagy and Mitophagy.

A role of dentate gyrus mechanistic target of rapamycin activation in epileptogenesis in a mouse model of posttraumatic epilepsy

Rapamycin Plays an Anti-Epileptic Role by Restoring Blood-Brain Barrier Dysfunction, Balancing T Cell Subsets and Inhibiting Neuronal Apoptosis

Rapamycin Suppresses the Recurrent Excitatory Circuits of Dentate Gyrus in A Mouse Model of Temporal Lobe Epilepsy

[Efficacy of Brain-Targeted Rapamycin for Treatment of Epilepsy in Rats].

Blood-brain barrier leakage after status epilepticus in rapamycin-treated rats II: Potential mechanisms

Advances in the mTOR signaling pathway and its inhibitor rapamycin in epilepsy

Inhibition of Mtorc2 Improves Brain Injury in Epileptic Rats by Promoting Chaperone-Mediated Autophagy

Rapamycin Promotes Autophagy and Reduces Neural Tissue Damage and Locomotor Impairment after Spinal Cord Injury in Mice.

Rapamycin Prevents Cerebral Stroke by Modulating Apoptosis and Autophagy in Penumbra in Rats

Inhibition of Mammalian Target of Rapamycin Attenuates Early Brain Injury Through Modulating Microglial Polarization after Experimental Subarachnoid Hemorrhage in Rats

A study on the protective mechanism of mTOR inhibitor Everolimus on brain injury after epilepsy

Mechanistic target of rapamycin (mTOR) signaling in status epilepticus

Inhibition of Mtor Pathway by Rapamycin Decreases P-glycoprotein Expression and Spontaneous Seizures in Pharmacoresistant Epilepsy

Recombinant Human Erythropoietin Protects Against Brain Injury Through Blunting the Mtorc1 Pathway in the Developing Brains of Rats with Seizures.

Rapamycin Suppresses Microglial Activation and Reduces the Development of Neuropathic Pain after Spinal Cord Injury.

Rapamycin Alleviates Neuronal Injury and Modulates Microglial Activation After Cerebral Ischemia

Effect of Chronic Administration of Low Dose Rapamycin on Development and Immunity in Young Rats